In a significant development for mental health treatments, Enveric Biosciences (NASDAQ: ENVB) has secured its first U.S. patent for a novel series of compounds that could transform how we approach neuropsychiatric disorders. The company’s EVM401 Series represents a growing class of psychedelic-inspired therapies designed to provide the benefits of traditional psychedelics without the hallucinogenic effects that can limit their clinical use.
